Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diameter-dependent effects of nanopillar arrays on PEEK bioactivity and soft tissue integration.

Journal of nanobiotechnology·2026

Same author

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Nature medicine·2025

Same author

Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score.

Frontiers in surgery·2025

Same author

Structural insights into a highly flexible zinc finger module unravel INSM1 function in transcription regulation.

Nature communications·2025

Same author

Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR.

Cancer research·2025

Same author

Elucidating the Cell Surfaceome to Accelerate Cancer Drug Development.

Cancer discovery·2024

Search research articles

Related Experiment Video

Updated: May 29, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

EGFR mutant lung cancer.

Yixuan Gong¹, William Pao

¹Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Current Topics in Microbiology and Immunology

|August 26, 2011

Summary

This summary is machine-generated.

Lung adenocarcinoma, a subtype of non-small cell lung cancer (NSCLC), presents distinct molecular profiles driven by EGFR mutations. Understanding these genetic drivers enables targeted therapies and overcoming resistance mechanisms.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Experiment Videos

Last Updated: May 29, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Traditionally, lung cancer treatment decisions relied on histology (NSCLC vs. SCLC).
Emerging research shows non-small cell lung cancer (NSCLC) subtypes, like lung adenocarcinoma, represent diverse molecular diseases.
Specific 'driver' mutations in the EGFR signaling pathway define lung adenocarcinoma subsets.

Purpose of the Study:

To focus on EGFR-mutated NSCLC as a clinically relevant molecular subset.
To explore defined mechanisms of drug sensitivity and resistance to EGFR tyrosine kinase inhibitors.
To highlight the development of strategies to overcome acquired resistance.

Main Methods:

Analysis of genetic drivers in lung adenocarcinoma.
Investigation of EGFR signaling pathway mutations.
Review of drug sensitivity and resistance mechanisms.

Main Results:

EGFR mutations define distinct subsets of lung adenocarcinoma.
These mutations correlate with sensitivity and resistance to targeted therapies.
Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors have been identified.

Conclusions:

Knowledge of tumor genetic drivers facilitates rational targeted therapy.
EGFR-mutant NSCLC serves as a model for personalized cancer treatment.
Ongoing research aims to overcome acquired resistance for improved patient outcomes.